PRODUCT NEWS
CONSUMER STAMP OF EXCELLENCE FOR NEXIUM CONTROL
Walton Oaks, 3rd May 2016 - Pfi zer’s heartburn medication, Nexium Control® (esomeprazole), has been announced as General Healthcare Product of The Year in the 2016 Consumer Survey of Product Innovation.
Mike Nolan, CEO of Product of the Year, commented: “This year, the healthcare category has largely been shaped by the increasing consumer demand for convenience, especially when it comes to short term annoyances such as headaches and heartburn. The winner of Product of the Year’s general healthcare category, Nexium Control®, is an outstanding example of a product developed in response to this. Just one pill delivers up to 24-hour protection so users could be provided with a one-step solution to heartburn that helps them to continue their day without missing a beat. We’re delighted to give it our trusted stamp of approval.”
Product of the Year is the UK’s largest independent survey into product innovation with more than 11,500 consumers voting in a survey conducted by TNS. 86% of consumers say the endorsement of the Product of the Year logo makes them more likely to buy the product, and as many as 64% of
FOR IMMEDIATE RELEASE
CONSUMER STAMP OF EXCELLENCE FOR NEXIUM CONTROL
NEW GALPHARM NICOTINE REPLACE GUM – ‘HELPING SMOKERS SPEND LESS TO QUIT’
Walton Oaks, 3rd May 2016 - Pfizer’s heartburn medication, Nexium Control® (esomeprazole), has been announced as General Healthcare Product of The Year in the 2016 Consumer Survey of Product Innovation.
The award comes almost one year after the MHRA’s reclassification of Nexium Control®, the well-established proton pump inhibitor (PPI), which became available for consumers to purchase without a prescription in February 2015.
New Nicotine Replace Gum is the latest addition to the Galpharm nicotine replacement range, which now offers both nicotine replacement gum and lozenges that are as effective as leading brands at affordable prices. Each Galpharm Nicotine
Replace medicated chewing gum is available in two strengths, containing 2mg or 4mg of nicotine in a cooling and fresh tasting sugar free peppermint fl avoured gum.
Mike Nolan, CEO of Product of the Year, commented: “This year, the healthcare category has largely been shaped by the increasing consumer demand for convenience, especially when it comes to short term annoyances such as headaches and heartburn. The winner of Product of the Year’s general healthcare category, Nexium Control®, is an outstanding example of a product developed in response to this. Just one pill delivers up to 24-hour protection so users could be provided with a one-step solution to heartburn that helps them to continue their day without missing a beat. We’re delighted to give it our trusted stamp of approval.”
Galpharm Nicotine Replace 2mg Gum is suitable for smokers who smoke less than 20 cigarettes per day, and Galpharm Nicotine Replace 4mg Gum is suitable for smokers who smoke more than 20 cigarettes per day.
Product
consumers recognise the logo.1 1 Source: TNS Omnibus Data May 2013 2 Data on File. Based onresearch 2013 in 1,001 frequent heartburn sufferers, divided into fi ve segments based on attitudes on heartburn and treatment.
k/emc/medicine/29824. Last accessed May 2016. Nexium Control® has also been recognised in the OTC Marketing Awards as the OTC Launch of the Year, with judges commenting that the launch added “true innovation to the digestive health category.” Kristie Sourial, Senior Medical Manager for Nexium Control®, said: “We are proud to see Nexium Control® recognised as an example of a new product which helps to meet the needs of UK consumers, 8 million of which are frequent heartburn sufferers2
. Allowing frequent heartburn sufferers to have greater access 5532 Zeroderma quarter page advertorial PiF v3.qxp_5532 Zeroderma quarte to treatments with a long tolerability history,
Up to £1 million savings for NHS Scotland with Zeroderma
Galpharm Nicotine Replace 2mg Gum
3 Nexium Control Summary of Product Characteristics. Available at:
https://www.medicines.org.u
Galpharm Nicotine Replace 4mg Gum
Pack Size
96
pieces 96
Nexium Control® has also been recognised in the OTC Marketing Awards as the OTC Launch of the Year, with judges commenting that the launch added “true innovation to the digestive health category.”
Galpharm Nicotine Replace 2mg Lozenges
Galpharm Nicotine Replace 2mg Lozenges
Kristie Sourial, Senior Medical Manager for Nexium Control®, said: “We are proud to see Nexium Control® recognised as an example of a new product which helps to meet the needs of UK consumers, 8 million of which are frequent heartburn sufferers2. Allowing frequent heartburn sufferers to have greater access to treatments with a long tolerability history,
Galpharm Nicotine Replace 4mg Lozenges
Galpharm Nicotine Replace 4mg Lozenges
1 Source: TNS Omnibus Data May 2013 2Data on File. Based onresearch 2013 in 1,001 frequent heartburn sufferers, divided into five
VAMOUSSE®
segments based on attitudes on heartburn and treatment. 3Nexium Control Summary of Product Characteristics. Available at:
https://www.medicines.org.u k/emc/medicine/29824. Last accessed May 2016.
New to minor ailments! Vamousse® is a next generation Head Lice Treatment, proven to kill 100% of lice & eggs within 15 minutes of contact, meaning there is no need to reapply. Stock up on Vamousse this back to school season, so when head lice come to your town, you can help your customers Vamousse those varmints!TM
36s GSL 6 £3.99 36s 12s GSL GSL 6 10 £3.99 £1.35
pieces 12s
Legal
Product of the Year is the UK’s largest independent survey into product innovation with more than 11,500 consumers voting in a survey conducted by TNS. 86% of consumers say the endorsement of the Product of the Year logo makes them more likely to buy the product, and as many as 64% of consumers recognise the logo.1
category GSL
GSL GSL 3 3 10 £9.99 £9.99 £1.35
Case Size
RRP
By changing from branded emollients to the cost effective Zeroderma emollient range, NHS Scotland could save £1 million a year and one Scottish Health Board could save around £200,000 p.a.
The Zeroderma range of eight emollients are similar in formulation to around 50% of currently prescribed emollients and offer cost savings of up to 37%. They are all sodium lauryl sulphate (SLS) free and available on prescription.
Many Health Boards and Clinical Commissioning Groups (CCGs) have adopted the Zeroderma range onto their formularies and cost savings are being made without compromising on patient care.
To find out how much your Health Board could save visit our QIPP and Emollients toolkit at
www.qipp.trderma.co.uk, developed by Medicines Management teams it contains everything needed to implement product changes at practice level, as well as a guide to the savings your Health Board could make.
For further information or patient evaluation samples, email:
zeroderma@thorntonross.com or visit
www.trderma.co.uk
Thornton & Ross, Linthwaite, Huddersfield. HD7 5QH Phone: 01484 842217 | Web:
www.trderma.co.uk
SCOTTISH PHARMACIST - 47
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48